HC Wainwright Cuts Plus Therapeutics (NASDAQ:PSTV) Price Target to $5.50

Plus Therapeutics (NASDAQ:PSTV) had its price objective decreased by HC Wainwright from $8.00 to $5.50 in a report published on Friday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Plus Therapeutics’ FY2029 earnings at $0.95 EPS.

A number of other brokerages have also recently weighed in on PSTV. D. Boral Capital began coverage on shares of Plus Therapeutics in a research report on Monday, March 17th. They set a “buy” rating and a $9.00 price target for the company. Ascendiant Capital Markets dropped their target price on shares of Plus Therapeutics from $20.00 to $19.00 and set a “buy” rating for the company in a report on Monday, December 9th.

Plus Therapeutics Stock Performance

Shares of Plus Therapeutics stock opened at $1.16 on Friday. The stock has a 50 day moving average of $1.11 and a 200 day moving average of $1.24. The firm has a market capitalization of $6.84 million, a price-to-earnings ratio of -0.46 and a beta of 0.73. Plus Therapeutics has a fifty-two week low of $0.24 and a fifty-two week high of $2.67.

Plus Therapeutics (NASDAQ:PSTV) last released its quarterly earnings results on Thursday, March 27th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.16). The firm had revenue of $1.80 million during the quarter, compared to analyst estimates of $1.19 million. Analysts forecast that Plus Therapeutics will post -2.3 EPS for the current year.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.